GlassScriptPhysician profile
John Bennett Sissney
NPI 1154681401
$4,169.62
in general payments reported to CMS, 2019-2025
28 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $733 · 2021: $524 · 2022: $362 · 2023: $411 · 2024: $380 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $666.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $657.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $399.57 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $384.31 | 2019-2025 | |
| Amgen INC. | $338.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $338.03 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.87 | 2019-2025 | Jardiance |
| Allergan, INC. | $172.70 | 2019-2020 | |
| Lilly USA, LLC | $146.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $82.16 | 2019-2020 | |
| Exact Sciences Corporation | $76.63 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $70.25 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $55.13 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $53.60 | 2021-2023 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $47.78 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.90 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $43.78 | 2022-2025 | |
| Genentech USA, INC. | $36.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.14 | 2019-2025 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $31.68 | 2019 | |
| Ironwood Pharmaceuticals, INC | $30.98 | 2019 | |
| Shire North American Group INC | $29.31 | 2019 | |
| Insulet Corporation | $19.12 | 2025 | Omnipod |
| Cashflow Solutions, LLC | $18.61 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Ironshore Pharmaceuticals INC. | $16.18 | 2019 | |
| Mylan Specialty L.P. | $14.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.97 | 2019 | |
| Bardy Diagnostics, INC. | $13.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sissney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.